A fermentation product of phytosterol including campestenone reduces body fat storage and body weight gain in mice.
(73/434)
Anti-obesity effects of a fermentation product of phytosterols including campestenone in ICR mice were investigated. Five-week-old male ICR mice were fed by the pair-feeding method for 8 wk. Experimental feed was prepared by adding TO-001, a phytostenone mixture produced by fermentation of phytosterols using Nocardioides simplex, at 0.25, 0.5, 1.0, or 2.0% or no additive to a high fat diet (fat 20%). Mice fed a stock feed (fat 5.6%) ad libitum were used as the standard growth group. In animals fed the high fat diet, control (no added TO-001) mice showed a weight gain that was about 10% higher than for the standard growth group. TO-001 reduced body weight dose-dependently. Final body weights of 0.5% and 1.0% TO-001-fed mice were lowered by about 9% and those of 2.0% TO-00 I-fed mice by about 12% compared with the control mice. Visceral and subcutaneous fat weight in mice fed TO-001 was significantly lower than that in mice fed the control diet. The concentrations of serum triglyceride (TG) and total cholesterol (TC) were significantly lower in the 1.0% and/or 2.0% TO-001-fed mice. Furthermore, levels of liver TG and TC were decreased in the TO-001-fed group. Increase of total lipid excretion in the feces was dose dependent. No obvious abnormalities due to consumption of TO-001 were detected by a blood biochemical examination, clinical observations or necropsy. The results suggested that TO-001, a fermentation product of phytosterols, may be a promising component of dietetic functional foods. (+info)
A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.
(74/434)
BACKGROUND: Thiazolidinediones such as rosiglitazone may have benefit in ameliorating human immunodeficiency virus (HIV) lipoatrophy. METHODS: HIV-positive patients receiving stable, protease inhibitor-containing highly active antiretroviral therapy with HIV lipodystrophy were prospectively randomized to rosiglitazone (4 mg/day) or placebo. The primary end point was the 24-week percentage change in arm fat by dual-energy x-ray absorptiometry (DEXA). Clinical and anthropometric evaluations, fasting lipid parameters, oral glucose tolerance testing, CD36 expression, quality of life measures, and DEXA scanning were performed at baseline and week 24. RESULTS: Seventy-eight of the 96 enrolled patients were evaluated. Median age was 46.8 years, 97.4% were male, and 54% were treated with thymidine analogues. Median baseline limb fat was 3.76 and 2.99 kg in the rosiglitazone and control groups, respectively. Median changes in arm, leg, trunk, and total body fat at 24 weeks were not significantly different between groups (7.1% vs. 5.0% [P=.94]; 0.1% vs. -2.4% [P=.90]; 1.2% vs. -1.4% [P=.81]; and 1.7% vs. 0.4% [P=.76]). There were no significant changes in secondary end points. There was no correlation between changes in body fat or treatment-arm and CD36 expression. CONCLUSIONS: This randomized, placebo-controlled trial did not show benefit of 4 mg/day of rosiglitazone on lipoatrophy or metabolic parameters in patients with HIV lipodystrophy. (+info)
Effect of sleep apnea syndrome on the circadian profile of cortisol in obese men.
(75/434)
It has been hypothesized that sleep apnea syndrome (SAS) increases hypothalamic-pituitary-adrenal axis activity and, through increased cortisol levels, participates in the pathophysiology of metabolic and cardiovascular complications. We compared the circadian profiles of cortisol in obese men with [obSAS+; apnea-hypopnea index (AHI) >or= 20/h] and without SAS (obSAS-; AHI +info)
Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices.
(76/434)
OBJECTIVES: Uridine abrogates mitochondrial toxicities of nucleoside reverse transcriptase inhibitor in adipocyte cell culture. We aim to study the effect of uridine supplementation on human adipocyte mitochondrial DNA (mtDNA) levels in subjects with human immunodeficiency (HIV) lipoatrophy. METHODS: Sixteen patients with lipoatrophy on stavudine-containing antiretroviral therapy were enrolled, and received NucleomaxX, a dietary supplement with a high bioavailability of uridine (36 g TID every other day for 16 weeks). Patients were then followed off-uridine for another 16 weeks. Highly active antiretroviral therapy remained unchanged during the trial. RESULTS: Fourteen patients completed the study. Two subjects dropped out before week 4 for study-unrelated reasons. No adverse events were noted throughout the study. HIV-1 RNA, CD4 counts, liver enzymes and hemoglobin remained unchanged. Body mass index, lactate, lipids, insulin and homeostasis model assessment of insulin resistance were unaltered. Fat and peripheral blood and mononuclear cell mtDNA levels did not correlate with each other and exhibited no changes throughout the study. Lipoatrophy scores by patients and physician improved significantly at weeks 16 and 32 compared to study entry. CONCLUSION: In this pilot study, NucleomaxX was safe, well tolerated without apparent deleterious effect on HIV indices. In contrast to in vitro data, NucleomaxX did not lead to changes in fat or blood mtDNA levels. (+info)
Patterns and interrelationships of body-fat measures among rural Chinese children aged 6 to 18 years.
(77/434)
OBJECTIVES: Our goal was to compare BMI and waist circumference with dual-energy radiograph absorptiometry-based measures of adiposity and to describe the pattern and interrelations of these surrogate and direct adiposity measures in prepubertal and pubertal rural Chinese children. METHODS: This was a cross-sectional study of 2493 children aged 6 to 18 years from a population-based cohort of twin pairs. Dual-energy radiograph absorptiometry-based measurements included total body fat, percentage of body fat, trunk fat, and percentage of trunk fat. Age- and gender-specific patterns and interrelationships among BMI, waist circumference, and dual-energy radiograph absorptiometry-based measurements were described by using smoothing plots and age- and gender-specific correlation analyses. RESULTS: In girls, BMI, waist circumference, total body fat, percentage of body fat, trunk fat, and percentage of trunk fat all increased linearly with age. In boys, BMI and waist circumference increased linearly with age, but total body fat, percentage of body fat, and trunk fat did not increase significantly with age. In both genders, percentage of trunk fat reached a nadir around 12 years of age and then increased with age. Before puberty (6-11 years), BMI and waist circumference were correlated well with total body fat, percentage of body fat, and trunk fat in both genders. During puberty (12-18 years), the correlations between BMI and each of the dual-energy radiograph absorptiometry-based measurements were higher in girls than in boys. Similar trends were found in the correlations between waist circumference and each of the dual-energy radiograph absorptiometry-based measurements. CONCLUSIONS: In this relatively lean rural Chinese population, BMI and waist circumference were highly correlated with each other and were good surrogates of total body fat, trunk fat, and percentage of body fat in prepubertal children of both genders and in pubertal girls. However, both BMI and waist circumference overestimated total and trunk fat, especially percentage of body fat in pubertal boys. (+info)
The effect of fat removal on glucose tolerance is depot specific in male and female mice.
(78/434)
Energy is stored predominately as lipid in white adipose tissue (WAT) in distinct anatomical locations, with each site exerting different effects on key biological processes, including glucose homeostasis. To determine the relative contributions of subcutaneous and visceral WAT on glucose homeostasis, comparable amounts of adipose tissue from abdominal subcutaneous inguinal WAT (IWAT), intra-abdominal retroperitoneal WAT (RWAT), male gonadal epididymal WAT (EWAT), or female gonadal parametrial WAT (PWAT) were removed. Gonadal fat removal in both male and female chow-fed lean mice resulted in lowered glucose levels across glucose tolerance tests. Female lean C57BL/6J mice as well as male and female lean FVBN mice significantly improved glucose tolerance, indicated by decreased areas under glucose clearance curves. For the C57BL/6J mice maintained on a high-fat butter-based diet, glucose homeostasis was improved only in female mice with PWAT removal. Removal of IWAT or RWAT did not affect glucose tolerance in either dietary condition. We conclude that WAT contribution to glucose homeostasis is depot specific, with male gonadal EWAT contributing to glucose homeostasis in the lean state, whereas female gonadal PWAT contributes to glucose homeostasis in both lean and obese mice. These data illustrate both critical differences among various WAT depots and how they influence glucose homeostasis and highlight important differences between males and females in glucose regulation. (+info)
Inflammation may modulate IL-6 and C-reactive protein gene expression in the adipose tissue: the role of IL-6 cell membrane receptor.
(79/434)
Only few studies have been addressed to the presence and regulation of C-reactive protein (CRP) gene expression in different districts of adipose tissue, and no study has investigated the role of adipose tissue in presence of inflammation. Therefore, the aim of this study was to investigate the inflammatory involvement of either adipose tissue or adipose cells (adipocytes and stromal cells, respectively) in patients with chronic inflammatory disease, focusing on regional adipose tissue CRP gene expression. Eighteen patients with inflammatory disease and 14 healthy controls were enrolled. All subjects underwent specific surgical procedures. Inflamed and noninflamed patients provided samples of subcutaneous and/or omental adipose tissue. All samples were analyzed by RT-PCR and real-time PCR for specific gene expression. In addition, both adipocytes and stromal cells were studied by real-time PCR and immunoprecipitation to evaluate either gene or protein expression of CRP. Our results (real-time PCR) demonstrated a higher gene expression of CRP, IL-6, and both IL-6 membrane receptors in subcutaneous samples of inflamed patients than in healthy controls. Furthermore, in omental fragments of inflamed patients, an enhanced mRNA abundance of the same genes, compared with subcutaneous, was observed. The results obtained at cellular level did not provide evidence of any difference between adipocytes and stromal cell CRP gene expression, whereas immunoprecipitation demonstrated the presence of CRP in inflamed subjects. These results provide first-time evidence of the involvement of adipose tissue in the course of chronic inflammatory diseases, with a different degree of participation of the different adipose tissue districts. (+info)
Reducing effect of matrix metalloproteinase inhibitors on serum triacylglycerol in streptozotocin-induced diabetic rats and Zucker fa/fa rats.
(80/434)
In the course of the investigation of effects of newly synthesized matrix metalloproteinase inhibitors (MMPIs), FYK-1388, FYK-1352 and F61-1008, which have strong and broad matrix metalloproteinase (MMP) inhibitory activity, on wound healing in streptozotocin (STZ)-induced diabetic rats, strong reducing effects on serum triacylglycerol (TG) have been found. Namely, when examined using breaking wound strength as an index, MMPIs did not significantly facilitate wound healing in STZ-induced diabetic rats. Unexpectedly, however, the treatment of STZ-induced diabetic rats with MMPIs markedly lowered the serum level of TG without changing the blood glucose level. Among these compounds tested, FYK-1388 was the most effective, and the compound reduced serum concentrations of TG and cholesterol and levels of very low-density lipoprotein (VLDL)-TG and low density lipoprotein (LDL)-cholesterol in a dose-dependent manner. FYK-1388 did not affect serum levels of free fatty acids, high-density lipoprotein (HDL)-cholesterol, aspartate aminotransferase and alanine aminotransferase, mass of body fat, liver weights, and hepatic contents of TG and cholesterol. Moreover, treatment of Zucker fa/fa rats with FYK-1388 lowered serum levels of TG and cholesterol without changing blood levels of glucose and insulin. Since the structures of these MMPIs markedly differ from those of the hypotriglyceridemic drugs that are used clinically, it seems plausible that these MMPIs could be used as a new type of hypotriglyceridemic drug. (+info)